Cardiff Oncology Q1 2023: Cash $97M, first patient dosed in ONSEMBLE trial

Cardiff Oncology, Inc.

2023-Q1 EPS reported -$0.25 revenue$83,000

Cash, cash equivalents & short-term investments of $97M as of March 31, 2023; projected runway into 2025.
First patient dosed in Phase 2 ONSEMBLE trial of onvansertib for KRAS/NRAS-mutated metastatic CRC.
Appointed Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer.
Operating expenses $12.1M in Q1 2023, up from $11.1M in Q1 2022.
Net cash used in operations $8.7M in Q1 2023, compared to $10.2M in Q1 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 4, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.